Tenax Therapeutics Company
Tenax Therapeutics maintains an oxygen supply to stop disease and damage to tissues that occurs when the flow of oxygen is interrupted. Tenax Therapeutics is developingmedical products designed to deliver oxygen to specific tissues in the body that are deprived of oxygen. Oxycyte PFC is in Phase IIb clinical trials in Switzerland and Israel for traumatic brain injury. Tenax Therapeutics is developing a PFC-based topical cream that has potential benefits for dermatologic indications and wounds. Studies in this area were completed in India. Tenax Therapeutics has developed the DERMACYTE line of skin care products to address several common aging issues, such as fine lines, wrinkles, puffiness, skin tone, blemishes and more.
Total Funding:
$10 650 000
Headquarters:
Morrisville, USA
Funding Status:
IPO
Employee Number:
11-50
Estimated Revenue:
$10-50 Mn
Last Funding Type:
Post-IPO Secondary
Technology:
Specific disorder-related
Investor Type:
For Profit
Last Funding Date:
30.06.2020
Founded Date:
01.01.1967
Industry:
Treatment range